Travere Therapeutics ( NASDAQ:TVTX – Free Report ) had its price target trimmed by HC Wainwright from $32.00 to $18.00 in a report issued on Friday, MarketBeat.com reports. The firm currently has a buy rating on the stock. TVTX has been the subject of several other research reports. William Blair cut shares of Travere Therapeutics from an outperform rating to a market perform rating in a research report on Thursday. Wells Fargo & Company cut shares of Travere Therapeutics from an overweight rating to an equal weight rating and decreased their target price for the company from $24.

https://www.dailypolitical.com/2023/09/23/hc-wainwright-trims-travere-therapeutics-nasdaqtvtx-target-price-to-18-00.html

#dailypolitical